No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

Studies over the past 10 years strongly support an association between skeletal muscle mass (SMM) depletion and outcome in metastatic colorectal cancer (mCRC). Factors influencing SMM changes over time are, however, poorly studied.